Key result
The prognostic value of cardiac troponins for cardiovascular disease in patients with chronic kidney disease remains unclear due to diverse conclusions across different studies.
Why the study?
What is the prognostic value of cardiac troponins for cardiovascular disease risk stratification in patients with chronic kidney disease?
What is the prognostic value of cardiac troponins for cardiovascular disease risk stratification in patients with chronic kidney disease?
The utility of cardiac troponins for cardiovascular risk stratification in patients with chronic kidney disease remains challenging due to conflicting evidence.
Troponin use for CVD risk stratification in CKD warrants caution; leaves open the need for standardized prospective studies.
Cardiac Troponins and Chronic Kidney Disease, What do we Know? Cardiovascular disease (CVD) is the first cause of mortality in patients with chronic kidney disease. Identifying patients at high risk for CVD is a diagnostic challenge for nephrologists and other clinicians. In the last decades, new biomarkers of myocardial damage have appeared, such as cardiac troponins. Their prognostic value has been widely studied in patients with impaired renal function. However, it has not yet been possible to make a good prognostic stratification of these patients, since the conclusions of the different studies are diverse.
No takes yet. Share an insight, caveat, or question.
Marián Goicoechea (2013) conducted a review in Chronic Kidney Disease. Cardiac troponins was evaluated. The prognostic value of cardiac troponins for cardiovascular disease in patients with chronic kidney disease remains unclear due to diverse conclusions across different studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: